"Frutto dell’alleanza tra soggetti pubblici e appartenenti al privato sociale, l’Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST è riferimento nazionale in campo oncologico. La sua missione consiste nel promuovere e realizzare attività di cura, studio e ricerca, in particolare ricerca traslazionale. Operativo dal 2007 all’interno delle strutture dell'ex Ospedale Civile di Meldola (Forlì-Cesena) ha sedi a Forlì, Cesena e Ravenna (Radioterapia) ed è riconosciuto quale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)."

During the past decade, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia" #1 collaborator was "AbbVie" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia" are "Aggressive Non-Hodgkin Lymphoma" (1 trials), "Classical Hodgkin Lymphoma" (1 trials), "Hodgkin Lymphoma" (1 trials), "Lymphoma, Mantle-Cell" (1 trials) and "Refractory T-Cell Lymphoma" (1 trials). Many other conditions were trialed in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia" in a lesser frequency.

Most popular intervention types in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bleomycin" (1 trials), "Cyclophosphamide" (1 trials), "Dacarbazine" (1 trials), "Daratumumab" (1 trials) and "Doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".